What is Tessera Therapeutics?
Tessera Therapeutics is an early-stage life sciences enterprise pioneering the field of Gene Writing. Unlike traditional gene editing, which often relies on cutting DNA, Gene Writing offers scientists and clinicians the ability to write small and large therapeutic messages directly into the genome. This approach seeks to cure diseases at their source, providing a versatile and potentially curative solution for a wide range of genetic conditions. The company operates at the intersection of advanced biotechnology and computational biology, positioning itself as a critical player in the future of personalized medicine and genomic engineering.
How much funding has Tessera Therapeutics raised?
Tessera Therapeutics has raised a total of $580M across 3 funding rounds:
Series A
$50M
Series B
$230M
Series C
$300M
Series A (2020): $50M with participation from Flagship Pioneering
Series B (2021): $230M led by Softbank Vision Fund 2i, Alaska Permanent Fund Corporation, Qatar Investment Authority, and Altitude Life Science Ventures LLC
Series C (2022): $300M supported by Artis Ventures Management Iii, Alaska Permanent Fund, Altitude Life Science Ventures, and Cormorant Asset Management
Key Investors in Tessera Therapeutics
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio and Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
Alaska Permanent Fund
APFC is an independent state entity that prudently invests and manages the assets of the Alaska Permanent Fund, specializing in long-term financial sustainability through diversified investment portfolios.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm driven by a deep focus on fundamental scientific principles, supporting innovative companies in biotech and allied sectors.
What's next for Tessera Therapeutics?
With the recent influx of capital, Tessera Therapeutics is well-positioned to accelerate its research and development initiatives. The strategic focus will likely shift toward expanding its internal pipeline and refining its Gene Writing platform for broader therapeutic applications. As the company moves into its next phase of growth, the emphasis will remain on validating its technology through rigorous preclinical studies and preparing for the complexities of clinical-stage development. The continued support from its diverse investor base provides the necessary runway to navigate the long-term regulatory and scientific hurdles inherent in pioneering novel genomic therapies.
See full Tessera Therapeutics company page
